key: cord-0913123-e1iy6hj1
authors: Choi, In-Jeong; Na, Woonsung; Kang, Aram; Ahn, Myun-Hwan; Yeom, Minjoo; Kim, Hyung-Ouk; Lim, Jong-Woo; Choi, Seong-O; Baek, Seung-Ki; Song, Daesub; Park, Jung-Hwan
title: Patchless administration of canine influenza vaccine on dog’s ear using insertion-responsive microneedles (IRMN) without removal of hair and its in vivo efficacy evaluation
date: 2020-06-13
journal: Eur J Pharm Biopharm
DOI: 10.1016/j.ejpb.2020.06.006
sha: 7d3d2770f100ebcddedd80d202805450b355e925
doc_id: 913123
cord_uid: e1iy6hj1

Microneedles provide the advantages of convenience and compliance by avoiding the pain and fear of needles that animals often experience. Insertion-responsive microneedles (IRMN) were used for administration to a hairy dog without removing the dog’s hair. Canine H3N2 vaccine was administered with IRMN attached to the dog’s ears ex vivo and the conventional microneedle system (MN) was administered for 15 min to compare puncture performance and delivery efficiency. The vaccine was also administered to compare antibody formation using IRMN with the use of intramuscular injection. The veterinarian observed the behavior of the dog during the course of the administration and compared the response to IRMN with that of intramuscular administration. The tips of IRMN were separated from the base and delivered into the hairy skin successfully. Puncture performance of IRMN were the same as that of coated microneedles (95%), but delivery efficiency of IRMN were 95% compared to less than 1% for coated microneedles. The H3N2 vaccine inoculated into the dog's ears showed the same antibody formation as the intramuscular injection. The dog appeared to be more comfortable with IRMN administration compared to syringe administration. IRMN are the first microneedle system to deliver a canine vaccine successfully into a hairy dog without removal of the dog’s hair. The use of IRMN can provide both convenience and compliance for both the dog and the owner.

Various formulations and delivery systems have been developed to provide for the delivery of drugs and vaccines into animals, including dogs, via oral, intramuscular, subcutaneous, and topical administration [1] [2] [3] [4] [5] [6] . Among these delivery methods, intramuscular administration has been the most widely used [6] [7] [8] . Currently, most companion animals receive vaccines for diseases such as Distemper, Hepatitis, Parvovirus, Parainfluenza infection, and Leptospira (DHPPL), corona virus, kennel cough, rabies, and influenza virus via injection into the subcutaneous skin layer or muscle [9] [10] [11] . These needle-based injections require a high volume of the drug to produce sufficient immunity, and such high-volume administration can evoke pain responses and the formation of a lump when the vaccine is inoculated using the wrong route, which in turn can trigger a hypersensitivity reaction that may require application of additional fluid or immunosuppressive treatment [12] [13] [14] [15] .

Canine influenza virus (CIV) is a serious pathogen that causes respiratory disease and hemorrhagic pneumonia, and it can also provoke secondary infection of bacteria, all of which can elevate the animal death rate [16] . H3N2 CIV originated from avian host, and it was isolated for the first time in dogs in South Korea in 2007, spreading to the US in 2015 [16, 17] . Intramuscular (IM) administration of H3N2 CIV vaccine stimulates serum antibody production, but this method of administration has significant limitations, including the need for trained health staff, a cold chain system, and a large storage space and facilities [15, [18] [19] [20] [21] . Dangerous waste, cross-contamination, and thermal instability of the vaccine are additional problems involved in the IM administration of liquid formulations [22] [23] [24] [25] . The administration of the vaccine using microneedles can overcome the limitations of IM administration.

Microneedle systems have been introduced to overcome the limitations of administration 6 using large needles such as syringes [24] [25] [26] [27] . Microneedles (MN) are a drug delivery system using microstructures with a length of several hundred micrometers. MN can deliver active pharmaceutical ingredients (API) into the skin layer with minimal pain regardless of the molecular weight or polarity of API [28] [29] [30] [31] [32] . Thus, MN allow a variety of drugs to be delivered into animals such as dogs with minimal pain and fear [15, [32] [33] [34] . In our study, a vaccine was delivered into dogs using microneedles, and successful antibody formation was obtained.

Vaccine microneedles have the advantages of skin immunization because there are immune cells in the skin layer such as derma dendritic cells (DDCs) and Langerhans cells (LCs) [6, [35] [36] [37] [38] [39] . For this reason, It can be applied to intradermal application with less dose, it can be induced to similar or more immune responses compared with intramuscular injection [6, 36, [40] [41] [42] [43] . In order to deliver the necessary amount of drug with dissolving microneedles (DMNs) or coated microneedles (CMNs), sufficient attachment time is needed, which requires the use of a patch. Therefore, the final MN product, called a microneedle array patch (MAP), consists of MNs and a patch. In the case of humans with little hair, there is no problem attaching patches, but MNs cannot be attached to the hairy skin surface of animals, so hair must be removed in order to insert the MNs into the skin. [27, [44] [45] [46] . A microneedle array patch (MAP) has been developed for human use that can be attached to relatively hairless arms or hands, but it is impossible to attach the MAP to a hairy site of the human body [47] [48] [49] . Therefore, a new microneedle system needs to be developed for attachment to hairy animal skin without removal of hair, and instructions for implementing the new system for animals are necessary.

In this study, we utilized a new system of insertion-responsive microneedles (IRMN) [25, 50] to administer H3N2 CIV vaccine to a dog's ear without removing the dog's hair. IRMNs are similar to dissolving microneedles (DMNs), but DMNs must be attached for a sufficient time for the drug to dissolve in the skin after insertion. IRMNs are MNs that separate the drug-coated water-soluble tips from the non-soluble base when they are inserted into the skin. The adhesion force at the interface of the water-soluble tips and the non-soluble base is controlled by the design and kind of material used to manufacture the MNs. Even if there is hair on the skin, IRMNs can be inserted into the skin by passing between the hairs, and the drug coated water-soluble tips are immediately separated from the base by the insertion force applied to the interface of the tips and the base. After the water-soluble tips coated with the drug are separated in the skin, both the drug and the tips are rapidly dissolved in body fluid. Therefore, since there is no necessity of attaching a patch, 100% of the loaded drug can be delivered by pressing on the patch with a finger for a few seconds.

In this study, the water-soluble tips were separated immediately after administration, and supplemented with 1% antibiotic-antimycotic in DMEM at 37°C and 5% CO 2 .

Inactivation of virus was conducted by 0.2% final concentration of formalin for 18 h at 37 °C and purified by ultracentrifugation at 100,000 × g, 4 °C for 4 h. Then, measurement of the pelleted whole viral protein content was detected by a colorimetric protein assay (Pierce™ BCA Protein Assay Kit, Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocols with albumin standard. The absorbance optical density was measured at 560 nm using a microplate reader (SpectraMax® i3x; Molecular Devices, San Jose, CA, USA).

The vaccine coating solution was prepared according to the following procedure. 

The master structure of a microneedle array has 97 microneedles that are 800 m high and 10 disk. The polydimethyl siloxane (PDMS, SYLGARD 184, Dow Corning, MI, USA) mold was prepared from master structure.

The microneedle array was manufactured in three steps [25, 50] : (1) preparation of tip, (2) preparation of base and integration of tips and base and (3) 

Step 3 involved coating the vaccine formulation on the IRMN: The coating solution containing the vaccine formulation was poured into a micro-well with 400 m of depth. To prevent the water-soluble tips from becoming blunt as a result of being dipped in the coating solution during the coating process, the IRMN were rapidly frozen by spraying liquid nitrogen on the sample [25] . The IRMN were then brought close to the coating solution and immersed in the well containing the coating solution at a rate of 1 mm/s. One second after immersion, the coated IRMN were removed from the solution. The coated IRMN were dried at room temperature for about 10 min. This coating process was repeated twice. The H3N2 CIV vaccine-insertion responsive microneedles were stored in a desiccator at 22 °C. (Figure 3 ).

The shapes of the IRMN and the H3N2CIV-IRMN were observed using an optical microscope (Eclipse TE2000-U, Nikon, Tokyo, Japan) and a scanning electron microscope (SEM, JSM-7500F, JEOL). 

To label the IRMN with lipophilic dyes (DiD), the viruses were incubated with 1,1′dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine (DiD) for 30 min at room temperature.

Unbound dye was removed using dialysis (MWCO 5K). The viral aggregates were then removed using 0.45-μm pore size filters. Fluorescent images of antigen-coated IRMN were 13 collected using a laser scanning confocal microscope (LSM700, Carl Zeiss, Jena, Germany).

In order to investigate whether IRMN can be administered to a dog's hairy ear without a hair removal process, dog ears (Cronex Co. Ltd., Hwaseong. South Korea) were obtained and tested. For visual observation of the successful delivery of IRMN, a coating solution containing Gentian violet was used instead of a vaccine coating solution, and the coating was performed by the same coating method as described above. A patch-type microneedle system was prepared to compare with a conventional microneedle system. The microneedle patch was made of only PLA in the same mold, the gentian violet formulation was coated with the same coating procedure, and the final microneedle array was fixed on the patch (MAP).

The dog ears (without the hair removed) were pinned onto the fixation plate, and IRMN and a MAP were administered separately to dog ears. Gentian violet-coated IRMN were pressed on the dog's ear for 10 s with the thumb and removed. A gentian violet-coated MAP was attached to the ear for 15 min after pressing the thumb on the dog's ear for 10 s. The intradermal delivery of the coating material was then confirmed by images under a camera (DSC-RX100M3, Sony, Tokyo, Japan). When the coating material is delivered into the skin, the colored formulation should not be left on the tips. Delivery efficiency was shown by comparing the number of dots left by the microneedle tips with the total number of microneedles.

To analyze antigen internalization in macrophage cells, ovalbumin (OVA) labeled with The cells were then washed with PBS and fluorescent images were collected using a laser scanning confocal microscope (LSM700, Carl Zeiss, Jena, Germany). Forty beagles (n = 10 per group) were vaccinated two times at 2-week intervals. The vaccination was performed using a previously described vaccination method [25] . The VC378-IM group was vaccinated by intramuscular (IM) administration and the VC378-IRMN group was vaccinated using IRMNs. These two groups each received 2 7 hemagglutinin unit (HAU) of VC378 antigen. A third group was vaccinated with one dose (500 μL vol.) of CaniFlu-Max (Bionote, Inc., Hwaseong, South Korea). The fourth group (placebo) was inoculated with phosphate-buffered saline (PBS). For IM administration, 0.5 ml of volume of vaccine was administrated into the caudal thigh muscles by using 22G needle. For microneedle vaccination, IRMN were placed on the skin without hair removal, pressed by gentle thumb pressure, held in place for 10 s, and detached from the skin. Serum was collected at the day of initial immunization and 14 days after the second vaccination.

The Canine Acute Pain scale of the Colorado State University (CSU) School of Veterinary Medicine, Fort Collins, CO, was used for the evaluation of the dogs' pain. This scale was developed as a teaching tool to help students recognize specific behaviors that may be indicative of pain. Two veterinarians monitored the dogs' behavioral and physiological responses during and after vaccination and determined appropriate pain scores ranging from 0 to 4, where 0 is comfortable, 1 is slightly unsettled, 2 is uncomfortable, 3 is unsettled, and 4 is screaming.

The HI assay was performed using a previously described method according to the WHO Manual (WHO Manual on Animal Influenza Diagnosis and Surveillance, http://www. who.int/iris/handle/10665/68026). Briefly, serum samples were treated with receptordestroying enzyme (RDE, Denka Seiken Co., Japan) in a 1:3 ratio (vol/vol) at 37 °C overnight and heat-inactivated at 56 °C for 30 min. After RDE treatment, six volumes of phosphatebuffered saline (PBS) were added to the RDE-treated serum samples. RDE-treated sera were serially diluted by 2-fold in a 25 μl volume in a 96-well plate. Virus was adjusted to 4 HAU/25

μl and added to each well. The HI titer was measured with 0.5% packed chicken red blood cells. The limit of detection was 1:10 for the HI assay.

Serum neutralizing antibody titers were measured in MDCK cells as described previously by Rowe et al. (1) , with modifications. Briefly, a monolayer of MDCK cells was cultured in minimal essential medium (MEM) supplemented with 10% FBS. Heat-inactivated sera were serially diluted 2-fold and mixed with 100 times the TCID50 of the VC378 virus. Neutralizing antibody titers were expressed as the reciprocal of the highest dilution of serum that was able to neutralize 100 times the TCID50 of the virus in cells. (2) where separation occurred, and a tip (3) coated with the vaccine formulation (Figure 4(b) ). The application of IRMN to the skin generated the separation of the tip (2) from the base (1) due to external forces caused by hard bone tissue, and the vaccine formulation was delivered together with the tip after separation.

The remaining tip in the skin was made of HA, a biocompatible, water-soluble, and biodegradable polymer. When the water-soluble vaccine formulation was coated on the IRMN, the coating solution could dissolve the tip. The tip could also become blunt as a result of dissolution, so that the IRMN could not penetrate into the skin. To overcome this difficulty, the IRMN were rapidly frozen to lower the dissolution rate of the tip during coating. This coating method allowed the water-soluble vaccine formulation to be applied on the IRMN without changing the geometry of the IRMN. As shown in Figure 4 

To investigate the distribution of the vaccine formulation on the IRMN, A/canine/VC378/2012 (H3N2) virus was labeled with lipophilic dyes (DiD) and then the formulation was coated on the IRMN using the freezing method ( Figure 5 ). Confocal laser scanning microscopy images of the resulting multilayer-coated microneedles showed local distribution of the vaccine formulation on the tip ends of the IRMN. 

Coated microneedles were placed on the patch (Figure 6(a) ) and pressed on a dog's hairy ear ex vivo for 10 s and then attached to the ear using a patch for 15 min (Figure 6(b) ). IRMN shown in Figure 6 (a') were pressed on the dog's ear for 10 s and removed ( Figure 6(b') ). As shown in the Figure 6 However, in the case of IRMN, the blue dots on the tip ends could not be seen by visual investigation (Figure 6(c') ). The tips of the IRMN were successfully delivered through the hairy skin. Ex vivo results showed ( Table 1 ) that IRMN are a successful system for delivering drugs through hairy skin. IRMN are the first system to deliver drugs successfully without hair removal. CMNs and IRMNs had different insertion times for achieving 100% delivery of the drug into the skin: less than 10 s for IRMNs and 10-30 min for CMNs. Thus, the insertion time for IRMNs and CMNs made a difference in the amount of drug delivered into the skin. 

To assess the immunogenicity of the IRMN vaccine in dogs, beagle dogs were immunized twice with the commercial canine influenza vaccine by administering inactivated VC378 vaccine either intramuscularly (i.m.) or with IRMN 14 days apart. Both vaccines induced HI titers against homologous strains (HI GMT of 21 to 30) (Figure 9(a) ). However, the IRMN vaccine induced statistically higher SN titers after prime vaccination in sera from immunized dogs, showing mean SN titers of >80 against the homologous VC378 strain at 14 days post vaccination (Figure 9 (b)). IRMN were successfully administered to hairy dogs without hair removal, resulting in the same antibody formation as with IM administration. In addition, administering IRMN inside the dogs' ears successfully induced antibody formation. neutralization assays of the VC378 viruses. The detection limit of each test was <10 HI.

Statistical significance of VC378 IRMN compared to each vaccination was determined by a t test (*p < 0.05; **p < 0.005).

Traditionally, dogs have been given drugs or vaccines administered by a syringe. However, administration by syringe has many difficulties, including inconvenience, low compliance, and pain. In this study, IRMN were administered inside dogs' ears without removal of hair, and vaccine-coated IRMN induced antibodies the same as those induced by IM injection.

Microneedles are a delivery method that facilitates the compliance of dogs because they cause less pain. However, administering a conventional microneedle array patch requires the removal of hair, which is not easy and can result in grooming-related stress. IRMN required only a few seconds of administration time without the use of a patch because they were composed of dissolvable hyaluronic acid tips and biocompatible polycaprolactone bases, and the tips were instantly separated from the base during microneedle insertion. The dogs used in our study showed less anxiety and discomfort as well as less pain because of the brief insertion time. IRMN can also be administered without removing hair. Thus, the use of IRMN can provide both convenience and compliance for both dogs and their owners.

Vaccine-coated IRMN induced the same level of antibody titer as that induced by IM administration of the vaccine. The comparable titers of the two insertion methods showed that the administration of vaccine with IRMN was successful. Local distribution of the vaccine formulation near the tips of the IRMN reduced the inconsistent delivery of the vaccine.

Microneedle tips and bases were separated immediately and successfully by the external force on the microneedles during skin insertion, as shown in the image of the base where no tips remained after separation ( Figure 6C') . However, puncture performance could be lowered if the tips were to be administered to skin covered with long and dense hair. Thus, the ear was a suitable site for vaccine administration using IRMN. The vaccine-coated tips were fully embedded in the skin for 10 s, and complete tip insertion was confirmed. However, insufficient pressure (less than 1 kg of force) on IRMN can cause incomplete insertion.

The use of IRMN is a new delivery method that can successfully deliver the desired dose of vaccine through the ears of hairy dogs. In addition to vaccines, various other drugs can also be delivered to the animals because of improved compliance. Therefore, the use of IRMN is a potential delivery system for animals in the future.

This work was supported by the Industrial Strategic Technology Development Program  A canine influenza vaccine was administered through a dog's ears using insertionresponsive microneedles (IRMN) successfully without removing the dog's hair.

 IRMN required only a few seconds of administration time without use of patch.

 Vaccine-coated IRMN induced the same level of antibody titer as that induced by intramuscular administration of the vaccine.

 IRMN are a potential vaccine administration system for use with hairy dog.

 IRMN can provide quick, painless, and convenient drug delivery into hairy animals.

Formulation and delivery of vaccines: ongoing challenges for animal management

Drug delivery systems: An updated review

Administration of substances to laboratory animals: routes of administration and factors to consider

Nonnutritive sucking and oral sucrose relieve neonatal pain during intramuscular injection of hepatitis vaccine

INTRAVENOUS, Intravenous, intramuscular, subcutaneous and intranasal administration of LH-FSH-RH: the duration of effect and occurrence of asynchronous pulsatile release of LH and FSH

Effect of vaccine administration modality on immunogenicity and efficacy, Expert review of vaccines

Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines

Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs

Efficient electrotransfection into canine muscle

Canine Rabies Vaccination. An Experimental Study of the Efficacy of the Single Intraperitoneal Injection Method with Phenol-Treated Vaccine

Canine babesiosis in a male Boerboel: Hematobiochemical and anatomic pathological changes in the cardiorespiratory and reproductive organs

Vaccine injection technique and reactogenicity-evidence for practice

Size doesn't matter: needle gauge and injection pain

Fillers: contraindications, side effects and precautions

Needlestick injuries in veterinary medicine

Influenza virus vaccine for neglected hosts: horses and dogs

Canine susceptibility to human influenza viruses (A/pdm 09H1N1, A/H3N2 and B)

Recent Approaches for Solid Dose Vaccine Delivery

Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles

Virus-like particle vaccine protects against H3N2 canine influenza virus in dog

Development of a thermostable microneedle patch for influenza vaccination

Freezing temperatures in the vaccine cold chain: a systematic literature review

Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions

Long-term stability of influenza vaccine in a dissolving microneedle patch

Insertionresponsive microneedles for rapid intradermal delivery of canine influenza vaccine

Preparation of H1N1 microneedles by a low-temperature process without a stabilizer

Skin immunization with third-generation hepatitis B surface antigen using microneedles

Microneedles for transdermal drug delivery

Microneedles for drug and vaccine delivery

Dissolving microneedles for transdermal drug delivery

Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery

Considerations in the use of microneedles: pain, convenience, anxiety and safety

Clinical administration of microneedles: skin puncture, pain and sensation

Safety Evaluation of Solid Polymer Microneedles in Human Volunteers at Different Application Sites

Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy

Recent insights into cutaneous immunization: how to vaccinate via the skin

Dendritic cells and the control of immunity

The cell biology of cross-presentation and the role of dendritic cell subsets

Transcutaneous immunization with Intercell's vaccine delivery system

Transdermal delivery of vaccines-Recent progress and critical issues

Microneedle technologies for (trans) dermal drug and vaccine delivery

Intradermal delivery for vaccine dose sparing: overview of current issues

Intradermal delivery of vaccines: potential benefits and current challenges

Rabies vaccination in dogs using a dissolving microneedle patch

A microneedle patch containing measles vaccine is immunogenic in non-human primates

Local dermal delivery of cyclosporin A, a hydrophobic and high molecular weight drug, using dissolving microneedles

Efficacy of a bleomycin microneedle patch for the treatment of warts

Human studies with microneedles for evaluation of their efficacy and safety

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled

Immediate separation of microneedle tips from base array during skin insertion for instantaneous drug delivery